Published in Gut on January 01, 2003
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut (2004) 3.55
S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci (2013) 1.52
Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol (2009) 1.43
Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life. Aliment Pharmacol Ther (2013) 1.42
Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol (2004) 1.31
Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.25
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Genetic approaches to functional gastrointestinal disorders. Gastroenterology (2010) 1.18
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
The role of genetics in IBS. Gastroenterol Clin North Am (2011) 1.07
Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil (2010) 1.04
Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World. J Neurogastroenterol Motil (2015) 1.04
Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol (2014) 1.03
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver (2011) 0.99
Changing face of irritable bowel syndrome. World J Gastroenterol (2006) 0.99
Genetics of irritable bowel syndrome. Am J Gastroenterol (2008) 0.98
Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis. Parasitol Res (2012) 0.98
Genetic determination of irritable bowel syndrome. World J Gastroenterol (2008) 0.97
T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation (2010) 0.93
Microflora modulation of motility. J Neurogastroenterol Motil (2011) 0.91
Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol (2013) 0.88
Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig Dis Sci (2009) 0.87
Impaired integrity of DNA after recovery from inflammation causes persistent dysfunction of colonic smooth muscle. Gastroenterology (2011) 0.86
From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil (2010) 0.85
Genes and environment in irritable bowel syndrome: one step forward. Gut (2006) 0.84
Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome. Exp Ther Med (2013) 0.83
Protocol for a randomized controlled study of Iyengar yoga for youth with irritable bowel syndrome. Trials (2011) 0.83
Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Exp Ther Med (2013) 0.83
Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis. World J Gastroenterol (2013) 0.82
Genes and irritable bowel syndrome: is there a link? Curr Gastroenterol Rep (2008) 0.82
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol (2014) 0.82
Food allergy in irritable bowel syndrome: new facts and old fallacies. Gut (2004) 0.81
Anxiety-depressive disorders among irritable bowel syndrome patients in Guilan, Iran. BMC Res Notes (2012) 0.81
Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol (2014) 0.80
Genetic epidemiology of irritable bowel syndrome. World J Gastroenterol (2015) 0.79
Pathophysiologic findings of irritable bowel syndrome in china. J Neurogastroenterol Motil (2012) 0.79
Genetics of human gastrointestinal sensation. Neurogastroenterol Motil (2013) 0.79
New paradigm for studying genetic contributions to irritable bowel syndrome. Dig Dis Sci (2012) 0.79
Molecular basis of the irritable bowel syndrome. World J Gastroenterol (2014) 0.78
High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome. J Clin Gastroenterol (2016) 0.78
Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests? World J Gastroenterol (2007) 0.78
Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therap Adv Gastroenterol (2010) 0.78
Irritable bowel syndrome: a review article. Middle East J Dig Dis (2010) 0.78
Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with irritable bowel syndrome. Gut Liver (2013) 0.76
Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora? Therap Adv Gastroenterol (2009) 0.76
Identifying and testing candidate genetic polymorphisms in irritable bowel syndrome: association with TNFSF15 and tumor necrosis factor-α Ann Gastroenterol (2013) 0.75
The overlap in the genetic pathogenesis of ulcerative colitis and irritable bowel syndrome. Dig Dis Sci (2013) 0.75
Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome. Intest Res (2017) 0.75
Anxiety, depression and distress among irritable bowel syndrome and their subtypes: An epidemiological population based study. Adv Biomed Res (2016) 0.75
Sex-Related Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome. Dig Dis Sci (2017) 0.75
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A (1997) 6.99
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature (1994) 4.37
Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet (1996) 4.23
Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum (1999) 2.39
Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut (1983) 2.39
Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation (1998) 2.29
In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet (1999) 1.94
Abnormal colonic fermentation in irritable bowel syndrome. Lancet (1998) 1.91
Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci (1993) 1.83
ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol (1999) 1.68
The putative role of inflammation in the irritable bowel syndrome. Gut (2001) 1.51
Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol (1998) 1.46
Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens (1999) 1.13
Sensory dysfunction and the irritable bowel syndrome. Baillieres Best Pract Res Clin Gastroenterol (1999) 0.86
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
Non-colonic features of irritable bowel syndrome. Gut (1986) 5.48
Antibody to the gastric campylobacter-like organism ("Campylobacter pyloridis")--clinical correlations and distribution in the normal population. J Med Microbiol (1986) 4.95
Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet (1984) 4.11
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut (2004) 3.55
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther (2003) 3.41
Is chest pain after sumatriptan oesophageal in origin? Lancet (1994) 3.34
Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther (2015) 2.90
Bran and irritable bowel syndrome: time for reappraisal. Lancet (1994) 2.68
Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ (2009) 2.51
Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut (1983) 2.39
Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation (1998) 2.29
Isolation of reovirus-like agents from patients with Crohn's disease. Lancet (1977) 2.24
A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol (2000) 2.21
Irritable bowel syndrome, chronic pelvic inflammatory disease and endometriosis: a comparison of symptomatology. Eur J Gastroenterol Hepatol (2004) 2.20
TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax (2000) 2.14
In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet (1999) 1.94
Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol (1997) 1.90
Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut (1997) 1.88
Ranking of symptoms by patients with the irritable bowel syndrome. BMJ (1989) 1.87
Bottle feeding, early gastroenteritis, and inflammatory bowel disease. Br Med J (1979) 1.83
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.82
Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (2004) 1.81
Hypnotherapy in severe irritable bowel syndrome: further experience. Gut (1987) 1.79
TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech (2000) 1.77
Review article: abdominal bloating and distension in functional gastrointestinal disorders--epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther (2007) 1.71
Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut (1990) 1.70
Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion (2004) 1.69
ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol (1999) 1.68
Long term benefits of hypnotherapy for irritable bowel syndrome. Gut (2003) 1.63
Oesophageal motility in the irritable bowel syndrome. Br Med J (Clin Res Ed) (1981) 1.63
Crohn's disease in a husband and wife. Lancet (1978) 1.61
A single-blind crossover comparison of fenoprofen, ibuprofen and naproxen in rheumatoid arthritis. Curr Med Res Opin (1974) 1.60
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) 1.57
Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut (2007) 1.50
'Nodular necrobiosis': a new cutaneous manifestation of Crohn's disease? Gut (1982) 1.49
The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. Transplantation (2000) 1.47
Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol (2001) 1.47
Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol (1998) 1.46
Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant (2002) 1.45
Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol (1999) 1.45
Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther (1997) 1.43
Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. Gut (1986) 1.41
Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant (1999) 1.40
What do patients with irritable bowel syndrome dream about? A comparison with inflammatory bowel disease. Dig Liver Dis (2002) 1.39
The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut (2002) 1.39
Arterial blood gas tensions during upper gastrointestinal endoscopy. Gut (1976) 1.39
More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology. Gut (1991) 1.37
Pulmonary function in patients with inflammatory bowel disease. Am J Gastroenterol (1980) 1.36
Double blind study of ispaghula in irritable bowel syndrome. Gut (1987) 1.35
A time-efficient and accurate strain estimation concept for ultrasonic elastography using iterative phase zero estimation. IEEE Trans Ultrason Ferroelectr Freq Control (1999) 1.34
Irritable bowel syndrome: diagnosis and management. BMJ (2006) 1.31
Antibodies to Campylobacter pyloridis in household contacts of infected patients. Br Med J (Clin Res Ed) (1987) 1.28
Symptomatology, quality of life and economic features of irritable bowel syndrome--the effect of hypnotherapy. Aliment Pharmacol Ther (1996) 1.26
Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut (2006) 1.26
Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer (2001) 1.23
Design of treatment trials for functional gastrointestinal disorders. Gut (1999) 1.23
Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration. Br Med J (Clin Res Ed) (1987) 1.22
Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol (2001) 1.19
Death from ischaemic heart-disease and malignancy in adult patients with coeliac disease. Lancet (1976) 1.19
Quality of life in irritable bowel syndrome. Pharmacoeconomics (2001) 1.14
Gastric mucosal lymphocyte subpopulations in pernicious anemia and in normal stomach. Clin Immunol Immunopathol (1983) 1.14
Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals. Dig Dis Sci (1989) 1.14
Ulcerative colitis in association with Takayasu's disease. Am J Dig Dis (1978) 1.13
Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens (1999) 1.13
Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil (2005) 1.13
Antigen-reactive cell opsonization (ARCO) and its role in antibody-mediated immune suppression. Immunol Rev (1980) 1.12
Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut (1991) 1.12
Antibodies to maize in patients with Crohn's disease, ulcerative colitis and coeliac disease. Clin Exp Immunol (1979) 1.11
Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int (1999) 1.11
Crohn's disease in husband and wife. Lancet (1981) 1.10
Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.10
Using pictures to improve communication between doctor and patient in functional gastrointestinal disorders. Aliment Pharmacol Ther (2014) 1.09
Hypnotherapy in irritable bowel syndrome. Lancet (1989) 1.09
Controlled trial of hypnotherapy in relapse prevention of duodenal ulceration. Lancet (1988) 1.08
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther (2007) 1.07
Immunological aspects of inflammatory bowel disease. Clin Gastroenterol (1976) 1.07
Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther (1996) 1.06
IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol (1998) 1.05
Exclusion diets in irritable bowel syndrome: are they worthwhile? J Clin Gastroenterol (1987) 1.05
Suppressor T cells in allogeneic models. Transplantation (1986) 1.05
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev (2007) 1.05